🔗 Share this article

Government ministers and leading parliamentarians have issued warnings that the United Kingdom's series of deals with Donald Trump are "lacking a solid foundation." This comes after revelations that a so-called "milestone" deal on drug pricing, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any formal legal text beyond broad headline terms outlined by government press releases.

Lacking Legal Footing

The deal on drug tariffs, described as a "landmark" achievement, remains an "agreement in principle" without detailed provisions. Critics have noted that the press releases from the UK and US governments describe the deal in markedly contrasting terms. The British version focuses on securing "zero per cent tariffs" as a singular success, while the American announcement concentrates on the agreement for the NHS to pay 25% more for new medications.

"There is a serious risk that the UK government has made commitments to raise drug prices in return for little more than a pledge from President Trump," said David Henig, a trade policy analyst. "We know he has a tendency for not honouring his word."

Wider Concerns Amidst a Suspended Agreement

Worries have been heightened by Washington's action to pause the high-value digital accord, which was previously heralded as "a generational step-change" in the bilateral relationship. The US pointed to a failure to advance from the UK on lowering trade barriers as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an initial accord have not been formally ratified by the US, despite a looming January deadline. "It is our belief that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have admitted unease that the government's agreements with the US are lacking substance. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another described the situation as the "prevailing condition" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, stated: "What is even more astonishing than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a reliable partner. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Officials have downplayed the risk of the US reneging on the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials concede that instability is inherent in dealing with the Trump administration. However, they contend that the UK has obtained tangible results for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is lower than the rate for the rest of the world, is a solid gain," one official said.

However, problems have surfaced in enacting the broader trade deal. Promised quotas on beef exports have yet to be finalized, and the pledge to "eliminate duties on UK metals" has is still pending, with tariffs remaining at 25%.

Looking ahead, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.